Ind Swift Laboratories Complete Financial Statements
In FY2025, Ind Swift Laboratories (INDSWFTLAB) reported revenue ₹171 Cr, net profit ₹8 Cr and EPS ₹1.00, with a net profit margin of 4.7% and ROE of 0.7%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see INDSWFTLAB stock live price.
11 Years of Data
2025 - 2015
Complete Financial Data Export
Profitability Ratios
Net Profit Margin
4.68%
2025 data
EBITDA Margin
11.11%
2025 data
Operating Margin
1.00%
2025 data
Return on Assets
0.56%
2025 data
Return on Equity
0.68%
2025 data
Balance Sheet Ratios
Current Ratio
19.22
2025 data
Equity Ratio
81.57%
2025 data
Asset Turnover
0.12
2025 data
INDSWFTLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
INDSWFTLAB YoY (Sept 2024 vs Sept 2025) — revenue +584.0%, EBITDA +1800.0%, expenses +529.2%.
Revenue Growth
+584.0%
Year-over-Year
EBITDA Growth
+1800.0%
Year-over-Year
Expense Growth
+529.2%
Year-over-Year
Assets Growth
-1.5%
Year-over-Year
Equity Growth
+44.5%
Year-over-Year
Operating Cash Flow Growth
+86.1%
Year-over-Year
Investing Cash Flow Growth
-292.9%
Year-over-Year
Financing Cash Flow Growth
-89.5%
Year-over-Year
INDSWFTLAB Income Statement — Revenue, EBITDA & Net Profit
Ind Swift Laboratories revenue ₹171 Cr, EBITDA ₹19 Cr, net profit ₹8 Cr, EPS ₹1.00 (2025) — net profit margin 4.7%. Explore INDSWFTLAB Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 171 | 359 | 167 | 178 | 25 | 987 | 44 | 145 | 297 | 315 | 316 | 295 | 318 | 328 | 288 | 321 | 243 | 229 | 256 | 255 | 234 | 204 | 216 | 235 | 202 | 207 | 193 | 212 | 187 | 213 | 251 |
| Expenses | 151 | 147 | 149 | 153 | 24 | 437 | 43 | 136 | 224 | 267 | 250 | 236 | 252 | 270 | 227 | 259 | 180 | 185 | 199 | 194 | 179 | 156 | 167 | 178 | 163 | 157 | 148 | 165 | 136 | 155 | 163 |
| EBITDA | 19 | 211 | 18 | 26 | 1 | 549 | 1 | 9 | 73 | 47 | 66 | 59 | 66 | 58 | 60 | 62 | 63 | 44 | 57 | 61 | 55 | 48 | 49 | 57 | 40 | 50 | 46 | 47 | 51 | 58 | 88 |
| Operating Profit Margin % | 1.00% | -7.00% | 2.00% | -1.00% | -99.00% | 17.00% | -29.00% | -6.00% | 23.00% | 12.00% | 19.00% | 18.00% | 19.00% | 12.00% | 19.00% | 17.00% | 24.00% | 18.00% | 21.00% | 21.00% | 22.00% | 19.00% | 21.00% | 21.00% | 15.00% | 19.00% | 21.00% | 19.00% | 19.00% | 16.00% | 18.00% |
| Depreciation | 7 | 7 | 7 | 9 | 0 | 20 | 0 | 6 | 13 | 9 | 14 | 14 | 16 | 82 | 16 | 15 | 14 | 28 | 14 | 21 | 20 | 22 | 20 | 20 | 23 | 28 | 23 | 23 | 26 | 25 | 25 |
| Interest | 2 | -27 | 1 | 1 | 0 | 3 | 0 | 10 | 21 | 22 | 20 | 21 | 24 | 24 | 24 | 22 | 24 | 24 | 24 | 24 | 25 | 21 | 25 | 26 | 29 | 27 | 28 | 29 | 23 | 5 | 22 |
| Profit Before Tax | 10 | 231 | 10 | 16 | 1 | 527 | 1 | -7 | 39 | 16 | 32 | 24 | 26 | -47 | 20 | 24 | 25 | -8 | 19 | 16 | 10 | 4 | 5 | 12 | -12 | -5 | -6 | -5 | 3 | 28 | 40 |
| Tax | 2 | 8 | 2 | 7 | 0 | 33 | 0 | -1 | 7 | 41 | 14 | 5 | 1 | 14 | 0 | -3 | 1 | 21 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 8 | 222 | 9 | 10 | 0 | 494 | 1 | -6 | 32 | -25 | 17 | 19 | 25 | -62 | 20 | 28 | 25 | -29 | 19 | 16 | 10 | 3 | 5 | 12 | -12 | -25 | -6 | -5 | 3 | 28 | 40 |
| Earnings Per Share (₹) | 1.00 | 32.96 | 1.28 | 1.17 | 0.07 | 83.55 | 0.16 | -0.82 | 5.36 | -4.25 | 2.92 | 3.29 | 4.29 | -10.40 | 3.36 | 4.65 | 4.14 | -4.94 | 3.18 | 2.71 | 1.68 | 0.60 | 0.77 | 1.95 | -2.57 | -5.21 | -2.91 | -0.98 | 0.72 | 6.21 | 8.67 |
INDSWFTLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
INDSWFTLAB total assets ₹1,438 Cr, total equity ₹1,173 Cr, total liabilities ₹ Cr (2025) — ROE 0.7%.
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 1,438 | 1,460 | 1,824 | 1,801 | 1,818 | 1,870 | 1,924 | 2,023 | 2,138 | 2,215 | 2,244 |
| Current Assets | 865 | 960 | 1,165 | 1,075 | 944 | 863 | 836 | 842 | 832 | 926 | 924 |
| Fixed Assets | 273 | 192 | 588 | 630 | 753 | 843 | 914 | 934 | 1,042 | 1,099 | 1,117 |
| Capital Work in Progress | 0 | 51 | 8 | 10 | 19 | 12 | 20 | 69 | 70 | 79 | 113 |
| Investments | 214 | 112 | 30 | 29 | 36 | 18 | 19 | 18 | 18 | 0 | 0 |
| Other Assets | 952 | 1,106 | 1,199 | 1,131 | 1,011 | 998 | 972 | 1,002 | 1,007 | 1,037 | 1,014 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 45 | 215 | 771 | 866 | 901 | 906 | 980 | 534 | 601 | 746 | 989 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 1,173 | 812 | 682 | 601 | 603 | 641 | 588 | 553 | 531 | 517 | 606 |
| Share Capital | 69 | 67 | 60 | 60 | 60 | 60 | 48 | 46 | 46 | 42 | 41 |
| Reserves & Surplus | 1,030 | 745 | 622 | 541 | 544 | 581 | 540 | 507 | 486 | 476 | 553 |
INDSWFTLAB Cash Flow Statement — Operating, Investing & Financing
Ind Swift Laboratories operating cash flow ₹-26 Cr, investing ₹-110 Cr, financing ₹69 Cr, net cash flow ₹-67 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -26 | -187 | 195 | 150 | 135 | 125 | -64 | 73 | 96 | 79 | 98 |
| Investing Activities | -110 | -28 | -13 | 5 | -10 | -9 | -13 | -17 | -31 | -29 | -35 |
| Financing Activities | 69 | 657 | -186 | -141 | -124 | -133 | 100 | -62 | -69 | -48 | -64 |
| Net Cash Flow | -67 | 443 | -4 | 14 | 1 | -17 | 23 | -6 | -4 | 3 | -1 |